Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

(A and B) Baseline torrential tricuspid regurgitation; (C and D) computed tomography scan simulation of the TRiFlO device; (E and F) the TRiFlO device consists of 3 anchors and a central tricuspid flow optimizer (TFO); anchors are secured at the commissures and the TFO targets the regurgitant area; (G and H) TFO opens during systole and closes in diastole thus targeting tricuspid regurgitation; (I and J) fluoroscopic imaging of the TRiFlO device positioned and then released; (K) acute procedural result; (L) 6 months’ follow-up demonstrating reverse remodeling of the right ventricle with moderate tricuspid regurgitation. Image and caption courtesy of Ussia et al. and JACC: Cardiovascular Interventions.

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.